Molecular imaging of RNA interference therapy targeting PHD2 for treatment of myocardial ischemia. Methods in molecular biology (Clifton, N.J.) Huang, M., Wu, J. C. 2011; 709: 211-221

Abstract

Coronary artery disease is the number one cause of morbidity and mortality in the Western world. It typically occurs when heart muscle receives inadequate blood supply due to rupture of atherosclerotic plaques. During ischemia, up-regulation of hypoxia inducible factor-1 alpha (HIF-1a) transcriptional factor can activate several downstream angiogenic genes. However, HIF-1a is naturally degraded by prolyl hydroxylase-2 (PHD2) protein. Recently, we cloned the mouse PHD2 gene by comparing the homolog gene in human and rat. The best candidate shRNA sequence for inhibiting PHD2 was inserted behind H1 promoter, followed by a separate hypoxia response element (HRE)-incorporated promoter driving a firefly luciferase (Fluc) reporter gene. This construct allowed us to monitor gene expression noninvasively and was used to test the hypothesis that inhibition of PHD2 by short hairpin RNA interference (shRNA) can lead to significant improvement in angiogenesis and contractility as revealed by in vitro and in vivo experiments.

View details for DOI 10.1007/978-1-61737-982-6_13

View details for PubMedID 21194030

View details for PubMedCentralID PMC3044180